Dear Editor,
The Magstim Bistim 2 is a transcranial magnetic stimulation (TMS) device comprising two Magstim 200 2 units, which can be used independently or connected via the BiStim Module for synchronous operation [1] . In Bistim Mode (BM), each device can be discharged independently or sequentially at timed intervals. The power output for each configuration is expressed as a percentage of the unit's maximum stimulator output (MSO) [2] . Importantly, MSO values are not equivalent across all modes [1, 3, 4] . For a given MSO value, the power output for the Magstim 200 2 is ~20% higher compared to BM [3, 4] .
Although differences in power output across modes are mentioned in some operating manuals [3, 4] , unstandardised reporting in published study protocols [5] makes it difficult to identify which modes are administered. Given the differences in power output between modes [3, 4] , and sensitivity of TMS protocols to stimulus pulse strengths [6] , using MSO values obtained from one mode (e.g., Magstim 200 2 ) to calculate stimulation parameters in another (e.g., BM) will lead to invalid, unreliable, and uninterpretable data.
We investigated whether Magstim 200 2 and BM MSO values are equivalent, and the impact of using Magstim 200 2 MSO values to calculate and obtain single-pulse TMS (spTMS) and paired-pulse TMS (ppTMS) measures in BM. We hypothesised that resting motor threshold (RMT) and peak-to-peak 1 mV test stimulus (TS) MSO values would be lower for the Magstim 200 2 , and using Magstim 200 2 MSO values to calculate spTMS and ppTMS parameters in BM would lead to systematically underpowered protocols.
We recruited 25 right-handed individuals aged 18 to 40 (mean age = 23.32; SD = 5.47).
Standard TMS inclusion/exclusion criteria were applied [7] . The Deakin University Human Research Ethics Committee approved the study. Participants provided informed, written consent in accordance with the Declaration of Helsinki.
Electromyography (EMG) recordings were obtained from the belly tendon of the first dorsal interosseous (FDI) of the right hand with surface Ag-AgCl electrodes (ground electrode over the ulnar styloid process). EMG recordings (PowerLab 4/35 (ADInstruments, New Zealand) were amplified (x1000), bandpass filtered (10 Hz -1 kHz), and digitised (10 kHz).
All protocols were delivered with the Magstim Bistim 2 (reference number: 3010-00) [2, 8] (Magstim Ltd, West Wales, UK). Descriptions of the Magstim Bistim 2 configurations are presented in Figure 1 . Magnetic stimuli were administered using a 70 mm Magstim figure 8coil (P/N: 3190-00).
[ Figure 1 here] The first dorsal interosseous (FDI) "hot spot" (left hemisphere) was defined as the scalp location producing the largest peak-to-peak MEP amplitude. RMT was defined as MSO values that evoked peak-to-peak MEP amplitudes > 50 µV in 5 of 10 trials. The 1 mV TS was defined as MSO values evoking average peak-to-peak MEP amplitudes of ~1 mV across 10 trials. RMT MSO, 1 mV TS MSO, and 1 mV MEPs (15 trials) were obtained with the 
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